Regulation of MDR1 Expression and Drug Resistance by CD44
CD44 对 MDR1 表达和耐药性的调节
基本信息
- 批准号:7442285
- 负责人:
- 金额:$ 29.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-07-01 至 2012-05-31
- 项目状态:已结题
- 来源:
- 关键词:ABCB1 geneAddressBindingBreast Cancer CellCD44 AntigensCD44 geneCancer BiologyCancer cell lineCell AdhesionCell membraneDataDeletion MutationDevelopmentDrug resistanceExtracellular MatrixFutureGenetic TranscriptionGlycosaminoglycansGoalsHyaluronanHybridsLinkLocalizedMalignant NeoplasmsMalignant neoplasm of ovaryMembrane ProteinsMulti-Drug ResistanceMusMutationMutation AnalysisNeoplasm MetastasisNull LymphocytesOvarianP-GlycoproteinP-GlycoproteinsPeritoneumPhenotypePhosphorylationPhosphotransferasesPhysiologicalProtein Kinase CProteinsRNARegulationResearch PersonnelRoleSiteSystemTestingTherapeutic InterventionTranscriptional RegulationTreatment FailureWomanXenograft ModelYeastscancer cellcell motilityin vivopreventprogramspromoterprotein protein interaction
项目摘要
DESCRIPTION (provided by applicant): Metastases and drug resistance are the major causes of treatment failure in cancer. These two important but not clearly related aspects in the biology of cancer have been extensively studied, but there is only indirect evidence that the phenotypes may be functionally linked. Two proteins, P-glycoprotein (P-gp) and CD44, are well known determinants of multidrug resistance and metastases, respectively. P-gp, the product of the MDR1 (ABCB1)-gene, is a transmembrane ATP-dependent transporter that confers drug resistance to cancer cells. CD44 is a membrane protein implicated in cell adhesion, motility and metastases and is the major receptor for hyaluronan, the principal glycosaminoglycan found in all types of mammalian extracellular matrices, such as the peritoneum, the most important site for ovarian cancer metastases. When studying the role of CD44 in cancer metastases, we unexpectedly uncovered two separate but possibly interrelated mechanisms linking CD44 and P-gp in drug resistance: CD44 physically interacts with P-gp and CD44 activates MDR1 and P-gp expression and this induction is dependent of CD44 Ser 291 phosphorylation. The mechanism appears to be transcriptional, since preliminary data shows that introduction of CD44 into null cells activates an MDR1 promoter construct. However the exact mechanism is not known. It is also unclear what is the mechanism that leads to increase drug resistance through this protein-protein interaction. Our overall goal is to investigate the mechanisms responsible for the development of drug resistance. Specifically, we will address the following aims: 1) To investigate mechanisms by which CD44 regulates MDR1 expression and P-gp function. 1A. To verify the physiological/pharmacological significance of the interactions between CD44 and P-gp. 1B. To determine the mechanism by which CD44 regulates MDR1 transcription. 2) To study the impact of CD44 expression on in vivo chemoresistance. 1A. To test the effect of CD44 in drug resistance in an ovarian cancer mouse xenograft model. 2B. To determine whether the dual expression of CD44 and P-gp is a predictive marker for drug resistance in women with ovarian cancer.
描述(申请人提供):转移和耐药性是癌症治疗失败的主要原因。癌症生物学中这两个重要但没有明确关联的方面已经得到了广泛的研究,但只有间接证据表明,表型可能在功能上有联系。P-糖蛋白(P-gp)和CD44分别是已知的多药耐药和转移的决定因素。P-gp是MDR1(ABCB1)基因的产物,是一种依赖于ATP的跨膜转运蛋白,对肿瘤细胞具有耐药性。CD44是一种与细胞黏附、运动和转移有关的膜蛋白,是透明质酸的主要受体,透明质酸是存在于所有类型的哺乳动物细胞外基质中的主要糖胺聚糖,如卵巢癌转移的最重要部位腹膜。在研究CD44在肿瘤转移中的作用时,我们意外地发现了CD44和P-gp在耐药中的两个独立但可能相互关联的机制:CD44与P-gp物理上相互作用,CD44激活MDR1和P-gp的表达,这种诱导依赖于CD44 Ser291的磷酸化。这一机制似乎是转录的,因为初步数据显示,将CD44导入零细胞可以激活MDR1启动子的构建。然而,确切的机制尚不清楚。目前还不清楚通过这种蛋白质-蛋白质相互作用增加耐药性的机制是什么。我们的总体目标是调查耐药的发生机制。具体地说,我们将解决以下目标:1)研究CD44调节MDR1表达和P-gp功能的机制。1A.验证CD44与P-gp相互作用的生理学/药理学意义。1B.目的:探讨CD44调控MDR1转录的机制。2)研究CD44表达对体内化疗耐药的影响。1A.目的:探讨CD44在卵巢癌小鼠移植瘤耐药中的作用。2B。目的:探讨CD44和P-gp双重表达是否是卵巢癌耐药的预测指标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lorna RODRIGUEZ-RODRIGUEZ其他文献
Lorna RODRIGUEZ-RODRIGUEZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lorna RODRIGUEZ-RODRIGUEZ', 18)}}的其他基金
Regulation of MDR1 Expression and Drug Resistance by CD44
CD44 对 MDR1 表达和耐药性的调节
- 批准号:
8082768 - 财政年份:2007
- 资助金额:
$ 29.64万 - 项目类别:
Regulation of MDR1 Expression and Drug Resistance by CD44
CD44 对 MDR1 表达和耐药性的调节
- 批准号:
7627383 - 财政年份:2007
- 资助金额:
$ 29.64万 - 项目类别:
Regulation of MDR1 Expression and Drug Resistance by CD44
CD44 对 MDR1 表达和耐药性的调节
- 批准号:
7841894 - 财政年份:2007
- 资助金额:
$ 29.64万 - 项目类别:
Regulation of MDR1 Expression and Drug Resistance by CD44
CD44 对 MDR1 表达和耐药性的调节
- 批准号:
7211906 - 财政年份:2007
- 资助金额:
$ 29.64万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 29.64万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 29.64万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 29.64万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 29.64万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 29.64万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 29.64万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 29.64万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 29.64万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 29.64万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 29.64万 - 项目类别:
Research Grant